The Domestic Advantage: Tariff-Resistant Industrials
Ford has lowered its annual profit forecast due to the financial impact of U.S. tariffs, creating a potential advantage for companies with resilient domestic supply chains. This theme identifies businesses that are well-positioned to outperform in a protectionist trade environment.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Ford's recent $2 billion profit reduction from tariffs demonstrates how trade policies can create winners and losers. Companies with domestic supply chains may gain significant competitive advantages when import duties pressure their globally-sourced competitors, potentially leading to stronger profitability and market outperformance.
What You Need to Know
This group focuses on industrial and manufacturing firms that operate primarily within the U.S., sourcing materials and producing goods domestically. This operational structure may shield them from the direct cost pressures of import duties that affect competitors with globalised operations, offering a tactical allocation for the current trade landscape.
Why These Stocks
These companies were handpicked by professional analysts based on their resilient domestic manufacturing and sourcing strategies. Each business is positioned to potentially benefit from protectionist trade policies, offering investors exposure to firms that could gain market share whilst competitors face tariff-related cost pressures.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+15.43%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 15.43% over the next year.
Stocks Rated Buy by Analysts
7 of 14 assets in this group are rated Buy by professional analysts.
Group Growth
This group averaged a 2.2% return last month.
Why You'll Want to Watch These Stocks
Domestic Manufacturing Edge
These companies operate with primarily U.S.-based supply chains, potentially giving them a cost advantage over competitors facing tariff pressures. When trade policies favour domestic production, these firms could see their margins improve.
Trade War Winners
Ford's $2 billion tariff hit shows how protectionist policies can create clear winners and losers. These industrial stocks are positioned on the winning side, potentially benefiting from competitors' increased costs.
Timely Market Opportunity
With trade tensions creating real financial impacts, this theme offers exposure to companies that could gain market share whilst globally-sourced competitors struggle with import duties and supply chain disruptions.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Beyond The App Store: Europe's New Rules
Following regulatory pressure from the European Union, Google has revised its Play Store rules to permit alternative payment systems. This change creates a new investment opportunity in companies poised to benefit from a more open mobile app ecosystem.
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Frequently Asked Questions
Everything you need to know about the product and billing.